Pleco Therapeutics receives FDA Orphan Drug Designation

Pleco Therapeutics receives FDA Orphan Drug Designation

Upworthy

Published

NIJMEGEN, The Netherlands, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV's lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML). PTX-252 is a novel molecular entity developed to…

#nijmegen #netherlands #fda #plecotherapeuticsbv #aml #ivotimmermans #plecotherapeutics #pleco #belgian #hyl

Full Article